This study aims to assess the clinical efficacy and safety of obinutuzumab in Chinese patients with indolent non-Hodgkin B-cell Lymphoma (predominantly Follicular lymphoma and Marginal zone lymphoma) in a real-world setting.

This study was a prospective, multicenter, non-interventional, real-world study. The study will be divided into two cohorts: Cohort 1 is the younger cohort (aged ≥ 18 and < 60 years at the start of treatment); Cohort 2 is the older cohort (aged ≥ 60 years at the start of treatment). Patients in this study will receive obinutuzumab-contained regimens according to the investigators' clinical opinion.

Inclusion Criteria:

• Age: Age ≥ 18 years at the start of treatment;
• Be diagnosed with grade 1-3a follicular Lymphoma, Marginal zone lymphoma;
• Previously untreated or relapsed or refractory patients;
• Patients who started treatment with otuzumab between June 2021 and April 2023.

Exclusion Criteria:

• Patients currently participating or planning to participate in any interventional clinical trial;
• Patients who, in the opinion of the investigator, are Discomfort for any other reason to participate in this study.

patients with FL and MZL who started treatment with otuzumab between June 2021 and April 2023.

all IPD that underlie results in a publication

starting 6 months after publication

IPD could be shared by contacting the corresponding author via email after publication.